DB
AUPH icon

Dmitry Balyasny’s Aurinia Pharmaceuticals AUPH Stock Holding History

Dmitry Balyasny’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-130,000
Closed -$978K – 2769
2022
Q3 		$978K Buy
+130,000
New +$1.13M ﹤0.01% 1825

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's AUPH Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 88,240 shares worth $1.5M. The stake represents ﹤0.01% of the portfolio and ranks #1979 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in AUPH as recently as Q3 2025.

Dmitry Balyasny first reported a position in AUPH in Q1 2017 and has held it in 17 quarters since. The position peaked at $14.4M in Q1 2023. 279 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Dmitry Balyasny held 88,240 shares of Aurinia Pharmaceuticals worth $1.5M as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Dmitry Balyasny position in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1979 holding.
  • Dmitry Balyasny first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
  • Dmitry Balyasny's Aurinia Pharmaceuticals position peaked at $14.4M in Q1 2023.
  • 279 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.